2. Acute generalized infection of the
reticuloendothelial system, intestinal lymphoid
tissue
Typhoid fever, also known simply as typhoid, is
a common worldwide bacterial disease,
transmitted by the ingestion of contaminated
food or water by Salmonella
It is characterized by severe systemic illness with
fever and abdominal pain
2/8/2019 ENTERIC FEVER 2
3. Pathogen
Infection with one of several Salmonella species
◦ Salmonella enterica serotype typhi (S. typhi)
◦ Salmonella paratyphi A
◦ Salmonella schottmuelleri (Salmonella paratyphi B)
◦ Salmonella hirschfeldii (Salmonella paratyphi C)
◦ Salmonella choleraesuis
CLINICALLY INDISTINGUISHABLE!
4. Transmission
Mainly in underdeveloped areas with poor sanitation
Humans are the only known hosts of Salmonella Typhi
fecal-oral Transmission
• close contact with patients or carriers
• contaminated water and food
2/8/2019 ENTERIC FEVER 4
5. Lifecycle
1. Oral uptake of pathogen
2. Distal ileum: migration into the Peyer patches and
disseminate via lymphatic or hematogenous route
3. Infection of macrophages (reticuloendothelial system)→
nonspecific symptoms
4. Spread from macrophages to the bloodstream: septicemia
→ systemic disease
5. Migrates back to intestine → excretion in feces
2/8/2019 ENTERIC FEVER 5
6. Clinical features
General
◦ Incubation period: 5–30 days (most commonly 7–14 days)
◦ If left untreated, three different disease stages, each lasting a
week, classically occur.
◦ After 3 weeks of disease: slow regression of symptoms; patients
may become chronic Salmonella carriers
◦ Typhoid fever is a systemic disease; it is not limited to the
gastrointestinal system!
◦ Typhoid fever must always be considered in the case of
persistent fever of unknown origin in endemic region!
2/8/2019 ENTERIC FEVER 6
7. Progression of illness
Week 1
◦Body temperature rises gradually
◦Relative bradycardia
◦Constipation or diarrhea
◦Headache
2/8/2019 ENTERIC FEVER 7
8. Week 2
◦ Persistent fever, but no chills; mostly unresponsive
to antipyretics
◦ Nonspecific abdominal pain and headaches
◦ Rose-colored spots appears on the lower chest and abdomen
(most commonly around the navel).
◦ Typhoid tongue: greyish/yellowish-coated tongue with red edges
◦ Yellow-green diarrhea, comparable to pea soup
◦ Neurological symptoms (delirium, coma)
2/8/2019 ENTERIC FEVER 8
9. Week 3
◦Clinical features of week 2
◦Additional possible complications include:
◦Intestinal bleeding and perforation
◦Hepatosplenomegaly
◦Rarely causes sepsis, meningitis, myocarditis, and
renal failure
2/8/2019 ENTERIC FEVER 9
10. Diagnostics
◦ Laboratory tests
◦ Anemia ,Leukopenia or leukocytosis, Abnormal liver function tests
◦ Pathogen detection
◦ Blood cultures: the most common used 80~90% positive during
the first 2 weeks of illness 50% in 3rd week not easy in 4th week
◦ Stool cultures often negative despite active infection, better in
3~4 weeks
◦ The bone marrow culture the most sensitive (98%) test specially
in patients pretreated with antibiotics
◦ Serology often nonspecifically elevated by
immunization or previous infections
2/8/2019 ENTERIC FEVER 10
11. Treatment
First stabilize and resuscitate the patient if it is required
Medication
Ciprofloxacin oral adults: 500 mg bid for 14 days
Ciprofloxacin IV 400 mg bid who cannot take oral medication
Ceftriaxone IV adults: 1-2 g daily for 7 days
Chloramphenicol 500-750mg qid orally or IV for 14 days
Azithromycin 1g stat, then 500mg-1g orally oD for 5-7 days
12. Complication
Chronic Salmonella carrier
◦ Definition: positive stool cultures 12 months after overcoming the disease
◦ Presentation: typically asymptomatic
◦ Treatment: ciprofloxacin administered for at least 1 month
◦ Chronic carriers are not allowed to work in the food industry.
◦ Increased risk for cholangiocarcinoma(bile duct cancer)
Intestinal hemorhage/perforation,Hepatitis,Myocarditis, Encephalopathy, Meningitis
2/8/2019 ENTERIC FEVER 12
13. Prevention
Food and water
◦ Vaccination is not entirely effective. Measure must
therefore be implemented to avoid exposure.
Vaccination
◦ Indication: The WHO recommends typhoid fever vaccination
to those traveling to high-risk areas (East and Southeast
Asia, Latin America, Africa).
2/8/2019 ENTERIC FEVER 13
14. Reference
Ryan ET, Andrews J. Epidemiology, Microbiology, Clinical
Manifestations, and Diagnosis of Enteric (Typhoid and Paratyphoid)
Fever. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate.
https://www.uptodate.com/contents/epidemiology-microbiology-
clinical-manifestations-and-diagnosis-of-enteric-typhoid-and-
paratyphoid-fever. Last updated November 27, 2017.
Brusch JL. Typhoid Fever. In: Bronze MS. Typhoid Fever. New York, NY:
WebMD. https://emedicine.medscape.com/article/231135. Updated
May 18, 2017. Accessed December 18, 2017.Centers for Disease Control
and Prevention. Typhoid & Paratyphoid Fever.
https://wwwnc.cdc.gov/travel/yellowbook/2018/infectious-diseases-
related-to-travel/typhoid-paratyphoid-fever. Updated May 31, 2017.
Ryan ET, Andrews J. Treatment and Prevention of Enteric (Typhoid and
Paratyphoid) Fever. In: Post TW, ed. UpToDate. Waltham, MA:
UpToDate. https://www.uptodate.com/contents/treatment-and-
prevention-of-enteric-typhoid-and-paratyphoid-fever. Last updated
November 27, 2017.
2/8/2019 ENTERIC FEVER 14
Editor's Notes
Typhoid fever is characterized by severe systemic illness with fever and abdominal pain [1]. The organism classically responsible for the enteric fever syndrome is S. enterica serotype Typhi (formerly S. typhi). Other salmonellae that may cause a similar clinical syndrome include:
●Salmonella paratyphi A
●Salmonella schottmuelleri (formerly Salmonella paratyphi B)
●Salmonella hirschfeldii (formerly Salmonella paratyphi C)
●Salmonella choleraesuis
An open label randomized trial of 82 children randomized to receive cefixime (20 mg/kg per day divided twice daily for five days) or ofloxacin (10 mg/kg per day divided daily for five days) demonstrated more rapid resolution of fever in the ofloxacin group (4.4 versus 8.5 days) [32]. There was one treatment failure in the ofloxacin group compared with 10 treatment failures and one relapse in the cefixime group. Another open label randomized trial among patients older than 15 years demonstrated that ofloxacin (200 mg orally twice daily for three days) was superior to ceftriaxone (3 g intravenously once daily for three days) [31].